

July 30, 2021

The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street, Mumbai – 400001

**Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated)
for the Quarter ended June 30, 2021**

Dear Sir/Madam,

Please find attached herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2021.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



Rajat Kalra
Company Secretary and Legal Head



Encl: As above

Dr. Lal PathLabs Limited records revenue of Rs 606.6 Cr in Q1 FY 2021-22

New Delhi, India, July 30, 2021 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2021

Consolidated Performance Highlights: Q1 FY 2021-22 vs Q1 FY 2020-21

Revenue: Rs 606.6 Cr, a growth of 128.1%
Normalised EBITDA at Rs 199.0 Cr with margin at 32.8%
PBT at Rs 179.3 Cr with margin at 29.5%, and
PAT Rs 133.7 Cr with margin at 22.0%

- Operating Revenue increased by 128.1% in Q1 FY22 to Rs. 606.6 Cr vs Rs 266.0 Cr in Q1 FY21
- Covid and Allied contributed 36.4% to Revenue in Q1 FY22 with 11.4 lac RTPCR tests
- Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q1 FY22 is at Rs. 199.0 Cr Vs Rs 54.0 Cr in the same quarter last year
- PBT is at Rs 179.3 Cr in Q1 FY22 vs Rs 38.1 Cr. in Q1 last year
- Profit after Tax in Q1 FY22 at Rs. 133.7 Cr as compared to Rs 28.4 Cr in Q1 last year
- Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

Financial Overview (Consolidated) in Rs Cr

Particulars	Q1 FY22	Q1 FY21	Gr %
Revenue	606.6	266.0	128.1%
Expenditure	417.6	217.6	
EBITDA	189.0	48.4	290.6%
Adj for Stock Based Compensation & CSR cost	10.0	5.6	
Normalised EBITDA	199.0	54.0	268.7%
<i>Normalised Margins</i>	<i>32.8%</i>	<i>20.3%</i>	
Other income	14.1	11.4	
PBT	179.3	38.1	370.0%
<i>Margins</i>	<i>29.5%</i>	<i>14.3%</i>	
PAT	133.7	28.4	370.4%
<i>Margins</i>	<i>22.0%</i>	<i>10.7%</i>	
EPS (Basic)	15.87	3.45	360.3%
EPS (Diluted)	15.84	3.44	360.0%



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2021 the company has 231 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,705 Patient Service Centers (PSCs) and 9,247 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Chief Financial Officer
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Mittali Bharti
Adfactors PR

+91 9871154558
mittali.bharti@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.